| Literature DB >> 31513558 |
Charlan D Kroelinger, Marion E Rice, Shanna Cox, Hadley R Hickner, Mary Kate Weber, Lisa Romero, Jean Y Ko, Donna Addison, Trish Mueller, Carrie Shapiro-Mendoza, S Nicole Fehrenbach, Margaret A Honein, Wanda D Barfield.
Abstract
Since 1999, the rate of opioid use disorder (OUD) has more than quadrupled, from 1.5 per 1,000 delivery hospitalizations to 6.5 (1), with similar increases in incidence of neonatal abstinence syndrome (NAS) observed for infants (from 2.8 per 1,000 live births to 14.4) among Medicaid-insured deliveries (2). CDC's response to the opioid crisis involves strategies to prevent opioid overdoses and related harms by building state capacity and supporting providers, health systems, and payers.* Recognizing systems gaps in provision of perinatal care and services, CDC partnered with the Association of State and Territorial Health Officials (ASTHO) to launch the Opioid Use Disorder, Maternal Outcomes, and Neonatal Abstinence Syndrome Initiative Learning Community (OMNI LC). OMNI LC supports systems change and capacity building in 12 states.† Qualitative data from participating states were analyzed to identify strategies, barriers, and facilitators for capacity building in state-defined focus areas. Most states focused on strategies to expand access to and coordination of quality services (10 of 12) or increase provider awareness and training (nine of 12). Fewer states focused on data, monitoring, and evaluation (four of 12); financing and coverage (three of 12); or ethical, legal, and social considerations (two of 12). By building capacity to strengthen health systems, state-identified strategies across all focus areas might improve the health trajectory of mothers, infants, and families affected by the U.S. opioid crisis.Entities:
Mesh:
Year: 2019 PMID: 31513558 PMCID: PMC6753967 DOI: 10.15585/mmwr.mm6836a1
Source DB: PubMed Journal: MMWR Morb Mortal Wkly Rep ISSN: 0149-2195 Impact factor: 17.586
Defined areas of focus targeting pregnant and postpartum women with opioid use disorder and infants prenatally exposed to substances, by state — Opioid Use Disorder, Maternal Outcomes, and Neonatal Abstinence Syndrome Initiative Learning Community, 2018
| Focus area | Definition | State | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AK | FL | IL | KY | NV | OH | PA | RI | TN | VT | WA | WV | ||
| Access to and coordination of quality services | Assessment of eligibility and availability of services to aid in treatment, referral, or recovery efforts (e.g., mental health services, child care, and transportation services), coordination of quality care, and integration of ancillary services | Yes* | Yes | —† | Yes | Yes | Yes | Yes | — | Yes | Yes | Yes | Yes |
| Provider awareness and training | Guidance, training, and education for providers on treatment protocols and guidelines to standardize care, screen and refer for treatment, and increase familiarity with additional clinical or social service resources and relevant state-specific laws and policies (e.g., plans of safe care) | Yes | — | Yes | Yes | Yes | Yes | Yes | Yes | — | Yes | — | Yes |
| Data, monitoring, and evaluation | Monitoring the burden of substance use or misuse through analysis of surveillance data, evaluation of programs, and policy or quality improvement initiatives | Yes | — | — | — | — | — | Yes | — | — | Yes | — | Yes |
| Financing and coverage | Medical coverage, reimbursement, and billing strategies for treatment of opioid use disorder during and after pregnancy, for prevention efforts, and to sustain long-term care provision | — | Yes | — | — | — | — | — | — | Yes | — | Yes | — |
| Ethical, legal, and social considerations | Programs, policies, or policy amendments to address social stigma and legal considerations (e.g., mandatory reporting) that affect uptake, access to, and provision of clinical, substance use, and mental health services | — | — | Yes | — | — | — | — | Yes | — | — | — | — |
Abbreviations: AK = Alaska; FL = Florida; IL = Illinois; KY = Kentucky; NV = Nevada; OH = Ohio; PA = Pennsylvania; RI = Rhode Island; TN = Tennessee; VT = Vermont; WA = Washington; WV = West Virginia.
* “Yes” indicates a state is working on strategies within the area of focus.
† Dash indicates a state is not working on strategies within the area of focus.
Existing barriers to and facilitators of addressing opioid use disorder among pregnant and postpartum women and infants prenatally exposed to substances — Opioid Use Disorder, Maternal Outcomes, and Neonatal Abstinence Syndrome Initiative Learning Community, state action plans,* 12 states, 2018
| Focus area | Existing barriers and facilitators |
|---|---|
|
| |
| Existing barrier | • Limited access to comprehensive clinical services, longer term MAT, and mental and behavioral health therapy because of limited number of specialized providers, delay in connection to care, variable transportation resources, and patient cost of services and treatment |
| • Limited access to services in rural areas because of reduced provider and social service availability, constrained health care infrastructure, and patient distance from care | |
| • Lack of comprehensive, coordinated, quality, continuous, and integrated care systems and social services for women with OUD and infants prenatally exposed to substances during care transition (e.g., from prenatal, obstetric, and delivery/neonatal intensive care unit to postpartum and pediatric care; from positive screen for OUD to treatment) | |
| Existing facilitator | • Telemedicine to facilitate access to care in areas with low provider capacity |
| • PQC infrastructure to facilitate provider coordination of services | |
| • Existing facility-based interventions or in-patient programs with resources on parenting and social skills for women with OUD and infants prenatally exposed to substances | |
| • Existing care and service referral processes for infants prenatally exposed to substances, including infants with NAS to ensure connection to appropriate care and services | |
| • Existing workgroups or task forces to focus on health and social services for infants prenatally exposed to substances, including infants with NAS | |
|
| |
| Existing barrier | • Lack of statewide provider awareness and experience with identifying and treating OUD, being a MAT prescriber, linking patients to other trained MAT providers, or broader issues affecting use or misuse of substances |
| • Inconsistent access to training and education for providers to better care for women with a positive screen for mental health conditions or substance use or misuse | |
| • Unclear reporting requirements and inconsistent application of evidence-based standards of care, including variable use of SBIRT for mental health or substance use or misuse in clinics and facilities | |
| Existing facilitator | • Statewide 24-hour telephone support lines to support provider knowledge of MAT prescribing guidelines |
| • PQC infrastructure to provide training opportunities (e.g., care bundles or waiver trainings) | |
| • Use of the SBIRT practice for provider training on mental health conditions and substance use | |
| • Leverage of current grant-funded programs to facilitate new training curricula for providers treating substance use | |
|
| |
| Existing barrier | • Inconsistent data collection and monitoring practices within a state, affecting measurement of services, assessment of burden, and reporting (e.g., OUD prevalence among pregnant and postpartum women, and plans of safe care for infants and caregivers) |
| • Limited in-state capacity to analyze data on prescription drug monitoring and OUD leads to delayed data analysis | |
| Existing facilitator | • Existing statewide data systems that identify women who test positive for substance use during pregnancy and infants prenatally exposed to substances |
|
| |
| Existing barrier | • Variable coverage of MAT treatment and counseling, ranging from full to partial or limited coverage for services (e.g., coverage gaps beyond 6 weeks postpartum) |
| • Limited provider understanding of insurance coverage for substance use treatment and counseling services, including MAT, which affects utilization of resources | |
| • Reimbursement issues, including lack of billing codes, coding discrepancies, and challenges with telemedicine or telehealth program reimbursement, resulting in limited provision of services | |
| • Lack of sustainable funding for programs, including PQCs, home visiting programs, screening and behavioral interventions, or drug treatment programs, that support quality care and services | |
| Existing facilitator | • Current billing and reimbursement structures that incorporate OUD recovery treatment, including inpatient substance use treatment and services |
|
| |
| Existing barrier | • Stigma associated with substance use, including discrimination and criminalization |
| • Fear of separation experienced by pregnant and postpartum women, from infants prenatally exposed to substance, including infants with NAS | |
| • Ethical concerns of health care providers about screening, reporting, and treating OUD during pregnancy | |
| • Gaps in provision of and access to social services, such as housing, transportation, and access to child care, for pregnant and postpartum women who use or misuse substances | |
| • Broader issues, such as polysubstance use, intergenerational poverty, and systemic factors and environmental conditions that might contribute to the opioid crisis that affect health outcomes | |
| Existing facilitator | • Statewide substance use campaigns currently include antistigma messaging, and promote care coordination including plans of safe care for infants and caregivers |
Abbreviations: MAT = medication-assisted treatment; NAS = neonatal abstinence syndrome; OUD = opioid use disorder; PQC = perinatal quality collaborative; SBIRT = screening, brief intervention, and referral to treatment.
* State action plans include an action document, presentation materials, and in-person discussions at the Opioid Use Disorder, Maternal Outcomes, and Neonatal Abstinence Syndrome Initiative Learning Community kick-off meeting in 2018.
† Alaska, Florida, Illinois, Kentucky, Nevada, Ohio, Pennsylvania, Rhode Island, Tennessee, Vermont, Washington, and West Virginia.
Strategies to address opioid use disorder among pregnant and postpartum women and infants prenatally exposed to substances — Opioid Use Disorder, Maternal Outcomes, and Neonatal Abstinence Syndrome Initiative Learning Community, state action plans,* 12 states, 2018
| Focus area | Strategies |
|---|---|
| Access to and coordination of quality services | • Add a focus on pregnant and postpartum women and infants to statewide opioid initiatives and obtain internal state stakeholder confirmation |
| • Communicate, collaborate, and coordinate within the state to avoid duplication of effort among agencies and organizations on OUD and NAS | |
| • Develop a MAT provider network map for pregnant and postpartum women with OUD using various state sources to share with stakeholders and the public | |
| • Implement evidence-based strategies to engage women in OUD treatment by building community-based service capacity to improve trauma-informed and family-centered care | |
| • Develop protocols and implementation processes for plans of safe care that include provision of services for postpartum women as caregivers for infants prenatally exposed to substances | |
| • Implement a PQC to coordinate OUD treatment networks, provide standards of care, disseminate communication and training on addressing stigma during care, and catalog social/wraparound services for pregnant and postpartum women and infants prenatally exposed to substances (e.g., nutrition and mental health services, housing services, parenting support, or early intervention) | |
| • Incorporate specific services and early education initiatives for infants prenatally exposed to substances into existing state frameworks and policies focused on infants and children | |
| • Improve care coordination and transition care from hospital discharge to pediatric services for postpartum women with OUD and infants prenatally exposed to substances | |
| Provider awareness and training | • Educate providers and the health care community on the importance of MAT and counseling services |
| • Educate providers and the health care community on requirements for plans of safe care requirements | |
| • Implement provider training on clinical standards and treatment using the prescription waiver to increase the number of active, listed, and licensed MAT providers | |
| • Train facility-based, prenatal, and community health care providers and program staff members on the SBIRT practice for pregnant women and caregivers of infants prenatally exposed to substances | |
| • Implement a PQC to develop clinical protocols, prescribing protocols, and standardized services for the treatment and management of pregnant and postpartum women with OUD, and the treatment and management of infants prenatally exposed to substances, including infants with NAS | |
| • Develop perinatal care practice standards and protocols for universal screening of prenatal and postpartum OUD, and facility-based screening for infants prenatally exposed to substances | |
| • Develop protocols for rapid quality improvement on care coordination of pregnant and postpartum women with OUD and infants prenatally exposed to substances | |
| • Develop a framework and training for implementing plans of safe care in all jurisdictions and communities | |
| Data, monitoring, and evaluation | • Develop protocols to measure and evaluate rapid quality improvement on care coordination of pregnant and postpartum women with OUD and infants prenatally exposed to substances (e.g., PQC) |
| • Develop a standardized data system to aid in identifying pregnant and postpartum women who use or misuse substances and infants prenatally exposed to substances, and collect information to meet Child Abuse Prevention and Treatment Act of 2016 reporting requirements | |
| • Identify standard data elements, data collection practices, and case definitions for OUD and NAS surveillance in birth hospitals | |
| • Establish a data-sharing process to identify eligibility for, referral to, and enrollment in special programs or social services for infants with NAS using data from multiple information systems to monitor early identification and connections to systems of care | |
| Financing and coverage | • Identify and expand coverage to increase access to inpatient or residential OUD treatment and comprehensive services for postpartum women with infants |
| • Collaborate with stakeholders to implement a care bundle for postpartum women with OUD and infants prenatally exposed to substances, including infants with NAS | |
| • Develop and implement a plan to provide and reimburse integrated, wraparound services for infants prenatally exposed to substances, up to age 1 year | |
| • Work with insurers, including Medicaid, to change prior authorization prescribing requirements for MAT, ensure full insurance coverage up to 1 year postpartum, and remove special requirements for prescribing approved medications | |
| • Identify sources for funding (e.g., Medicaid and federal grants) to support training efforts statewide and implementation of standardized clinical care | |
| Ethical, legal, and social considerations | • Develop nonstigmatizing messages for providers of substance use prevention and treatment and social and child welfare services on support of pregnant and postpartum women with OUD and infants prenatally exposed to substances, including those with NAS |
| • Train providers on implicit bias and antidiscrimination of pregnant women with mental health conditions or who use and misuse substances | |
| • Coordinate with statewide antistigma campaigns to address stigma toward pregnant and postpartum women who use and misuse substances, and infants prenatally exposed to substances | |
| • Standardize family-focused policies and practices across state agencies and health care organizations for postpartum women with OUD and infants prenatally exposed to substances |
Abbreviations: MAT = medication-assisted treatment; NAS = neonatal abstinence syndrome; OUD = opioid use disorder; PQC = perinatal quality collaborative; SBIRT = screening, brief intervention, and referral to treatment.
* State action plans include an action document, presentation materials, and in-person discussions at the Opioid Use Disorder, Maternal Outcomes, and Neonatal Abstinence Syndrome Initiative Learning Community kick-off meeting in 2018.
Alaska, Florida, Illinois, Kentucky, Nevada, Ohio, Pennsylvania, Rhode Island, Tennessee, Vermont, Washington, and West Virginia.